prostatic hyperplasia. However the mechanism responsible for the prostatic phenotype is unknown. To determine whether restoration of leptin levels normalizes proinflammatory status associated with MetS and modulates the prostate phenotype, we evaluated ob/ob mice across a range of criteria including prostate morphology and gene expression profile.
INTRODUCTION AND OBJECTIVES:
Epithelial barrier permeability appears to be increased in benign prostate hyperplasia (BPH), which correlates with E-Cadherin down-regulation. However, the cause of E-Cadherin down-regulation in BPH is unclear. Transforming growth factor beta 1 (TGF-b1) was found to be up-regulated in clinical BPH specimens and TGF-b1 overexpression induced BPH phenotype in mouse. TGF-b1 was reported to repress the expression of E-Cadherin in benign prostatic cells. However, whether and how TGF-b1 upregulation affects epithelial barrier permeability is unknown. This research is aimed at examining the change of tight junctions in BPH specimens and exploring the potential role of TGF-b1 in prostatic luminal epithelial permeability.
METHODS: Prostatic tissues derived from BPH patients or from either donors or patients with low volume prostate cancer were used to study tight junctions in BPH nodules and normal prostate tissues using transmission electron microscopy (TEM). These specimens were also used to study the expression of junctional proteins ZO-1, ZO-2, ZO-3 and E-Cadherin using immunofluorescence staining. Benign prostatic luminal epithelial cell lines BHPrE1 and BPH-1 were utilized to perform in vitro studies. Permeability and tight junctions of cell monolayers in trans-well inserts with/without TGF-b1 treatment were evaluated by trans-epithelium electrical resistant (TER) assay and FITC-dextran trans-well assay, and TEM respectively. Expression of junctional proteins following TGF-b1 treatment was determined by reverse transcription-polymerase chain reaction and western blot.
RESULTS: Tight junctions as well as junctional proteins were decreased in BPH tissues as compared to the normal prostate, suggesting the compromise of luminal epithelial barriers in BPH. TGF-b1 treatment decreased TER, increased FITC-dextran diffusion, and reduced the formation of tight junctions of cultured BHPrE1 and BPH-1 monolayers, indicating that TGF-b1 disrupted epithelial barrier and increased cell monolayer permeability. TGF-b1 treatment down-regulated the expression of E-Cadherin and Claudin 1 but up-regulated the expression of N-Cadherin, Snail and Slug in BHPrE1 and BPH-1.
CONCLUSIONS: Tight junctions together with junctional proteins are reduced in BPH specimens and the up-regulation of TGF-b1 is potentially an important mechanism leading to tight junction disruption in BPH pathogenesis. 
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hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
However, molecular mechanisms driving this connection are widely unknown and still await discovery. Metabolic hormones including ghrelin may be main players in the metabolic syndrome, but may also influence smooth muscle contractility and growth in various cell types. Smooth muscle contraction and growth may drive LUTS in the hyperplastic prostate. To address possible links between metabolic syndrome and BPH at molecular level, we examined effects of the ghrelin agonists L-692,585 and MK0677 on contraction of prostate tissues, and on proliferation of cultured stromal cells.
METHODS: Experimental models included human prostate tissues from radical prostatectomy and cell culture of human stromal cells (WPMY-1). Contractility was examined by organ bath. Proliferation was assessed by EdU assay and RT-PCR, and viability by CCK-8 assay. Molecular detection included RT-PCR, Western and double fluorescence staining.
RESULTS: RT-PCR, Western blot and fluorescence staining suggested ghrelin receptor (GHSR) expression in prostate tissues and WPMY-1 cells, which may be located to smooth muscle cells. MK0677 (300 nM) increased contractions of prostate strips induced by the a1-adrenergic agonist phenylephrine (p<0.001 for control vs. MK0677). Similarly, L-692,585 (100 nM) increased noradrenaline-induced contractions (p<0.001 for control vs. L-692,585). Consequently, L-692,585 enhanced neurogenic contractions induced by electric field stimulation (p<0.007 for L-692,585 vs. control). Treatment of WPMY-1 cells with MK0677 (300 nM, 24 h) increased the content of the proliferation markers Ki-67 (??CP control 0.9AE0.1, MK0677 1.8AE0.1, p<0.002) and cyclinD1 (control 0.99AE0.05, MK0677 1.5AE0.2, p<0.03). MK0677-induced proliferation was confirmed by EdU, where it turned out to be concentration-dependent with stronger increase observed at 100 nM than at 300 nM (24 h) (proliferation rate 56AE12% in controls, 76AE6% after 300 nM MK0677). In CCK8, effects of MK0677 were time-(24h, 48 h) and concentration-(100 nM, 300 nM) dependent, with MK0677 enhancing viability of WPMY-1 cells.
CONCLUSIONS: The ghrelin system is present and functional in the hyperplastic prostate, where it may promote smooth muscle contraction and growth of stromal cells. With this role, ghrelin may be a key mechanism linking the metabolic syndrome with development of BPH/LUTS.
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